Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have a high incidence of renal cell carcinoma (RCC) and high sodium glucose co-transporters 2 (SGLT2) expressions. The purpose of this study was to evaluate the anticancer activity of dapagliflozin as an SGLT2 inhibitor on RCC cell lines in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Haoyu, Liao, Liya, Chen, Hongtao, Kang, Qian, Shu, Xiaochun, Wang, Yanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Animal Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549715/
https://www.ncbi.nlm.nih.gov/pubmed/28763435
http://dx.doi.org/10.12659/MSM.902530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549715/
https://www.ncbi.nlm.nih.gov/pubmed/28763435
http://dx.doi.org/10.12659/MSM.902530

Ejemplares similares